GRCE
Grace Therapeutics, Inc. (GRCE) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
No disclosed environmental intensity metrics or transition targets were provided, limiting evidence that GRCE is better positioned than peers on emissions management.
Zero reported R&D-to-revenue may indicate limited investment in cleaner processes or product redesign versus peers that disclose dedicated decarbonization spending.
The absence of reported environmental disclosures prevents confirmation of stronger waste, water, or energy controls relative to peers, keeping the profile broadly average.
With no post-August 2025 filings or third-party evidence supplied, environmental positioning cannot be distinguished from peers on material regulatory or reputational factors.
Social
No workforce, safety, turnover, or customer-impact metrics were provided, so GRCE cannot be shown to outperform peers on core social risk management.
Zero stock-based compensation to revenue suggests limited dilution-related employee incentive burden, but it does not establish stronger labor practices than peers.
The lack of disclosed social KPIs leaves uncertainty around human-capital oversight, which weakens relative confidence versus peers with more transparent reporting.
Without evidence on diversity, training, or incident rates, GRCE appears neither materially advantaged nor disadvantaged versus peers on social factors.
Governance
Net debt to EBITDA of 0.54x indicates modest leverage, which supports governance resilience relative to more highly levered peers.
Zero stock-based compensation to revenue suggests restrained equity dilution, a governance positive versus peers with heavier pay-related shareholder pressure.
However, the absence of board, audit, ownership, and controversy disclosures limits evidence of stronger governance than peers on oversight quality.
With no filing-based governance detail provided, GRCE’s governance profile remains broadly middle-of-the-pack rather than clearly superior to peers.
Overall Score
GRCE screens as broadly middle-of-the-pack versus peers because limited disclosure and only modest balance-sheet discipline prevent evidence of a stronger ESG position.
Score Driver: Insufficient ESG Disclosure Versus Peers
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Grace Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
